



SANDU PHARMACEUTICALS LIMITED
REGD.OFFICE- PLOT NOS. 25,26,29 & 30, PILERNE INDUSTRIAL ESTATE,
MARRA, SALIGAO, BARDEZ GOA- 403 511.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER AND YEAR ENDED ON 30TH SEPTEMBER 2012

(in Lacs)

PART I Statement of Standalone Unaudited Results for the Quarter Ended 30/09/2012							
Particulars	3 months ended 30/09/2012	3 months ended 30/09/2011	Preceding 3 months ended 30/06/2012	Half Year to date figures for current period ended 30/09/2012	Half Year to date figures for previous period ended 30/09/2011	Previous year ended 31/03/2012	
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1 Income from operations	815.78	883.02	714.31	1,530.09	1,458.78	3,124.45	
(a) Net sales/income from operations (Net of excise duty)							
(b) Other operating income	815.78	883.02	714.31	1,530.09	1,458.78	3,124.45	
Total income from operations (net)							
2 Expenses	355.50	380.25	485.57	841.08	856.03	1,665.40	
(a) Cost of materials consumed							
(b) Purchases of stock-in-trade	47.31	98.71	(128.66)	(81.35)	(61.30)	(88.76)	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	104.45	45.52	81.41	185.86	59.22	239.44	
(d) Employee benefits expense	12.45	9.33	10.82	23.27	18.92	43.44	
(e) Depreciation and amortisation expense	250.33	304.73	225.80	476.13	501.97	1,124.86	
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	770.04	838.54	674.94	1,444.99	1,374.84	2,984.38	
Total expenses	45.74	44.48	39.36	85.10	83.94	140.07	
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	2.79	2.60	3.40	6.19	5.76	24.34	
4 Other income	48.53	47.08	42.76	91.29	89.70	164.41	
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	16.13	12.11	16.30	32.44	21.75	52.47	
6 Finance costs	32.39	34.97	26.46	58.86	67.95	111.93	
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)							
8 Exceptional items							
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	32.39	34.97	26.46	58.86	67.95	111.93	
10 Tax expense	5.00	2.86	5.00	10.00	10.00	63.56	
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	27.39	32.11	21.46	48.86	57.95	48.37	
12 Extraordinary items (net of tax expense Lakhs)	27.39	32.11	21.46	48.86	57.95	48.37	
13 Net Profit / (Loss) for the period (11 + 12)							
14 Share of profit / (loss) of associates*							
15 Minority interest *	27.39	32.11	21.46	48.86	57.95	48.37	
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	708.10	708.10	708.10	708.10	708.10	708.10	
17 Paid-up equity share capital (Face Value of the Share shall be indicated)							
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.39	0.45	0.30	0.69	0.82	0.68	
19.i Earnings per share (before extraordinary items) (of 10 /- each) (not annualised):							
(a) Basic							
(b) Diluted							
19.ii Earnings per share (after extraordinary items) (of 10 /- each) (not annualised):							
(a) Basic							
(b) Diluted							

PART II							
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding	3,895,310	3,895,310	3,895,310	3,895,310	3,895,310	3,895,310
	- Number of shares	55.01	55.01	55.01	55.01	55.01	55.01
	- Percentage of shareholding						
2	Promoters and Promoter Group Shareholding						
a)	Pledged / Encumbered						
	- Number of shares						
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)						
	- Percentage of shares (as a % of the total share capital of the company)						
b)	Non - encumbered	3,185,690	3,185,690	3,185,690	3,185,690	3,185,690	3,185,690
	- Number of shares	100.00	100.00	100	100	100	100
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	44.99	44.99	44.99	44.99	44.99	44.99
	- Percentage of shares (as a % of the total share capital of the company)						
B	Particulars			3 months ended (30/09/2012)		For SANDU PHARMACEUTICALS LIMITED	
	INVESTOR COMPLAINTS					SD/ UMESH B.SANDU MANAGING DIRECTOR	
	Pending at the beginning of the quarter			2 NIL		PLACE: MUMBAI	
	Received during the quarter			2		DATE: 9th November, 2012	
	Disposed of during the quarter			2 NIL			
	Remaining unresolved at the end of the quarter						